English-language podcasts

Lung Cancer Considered

ESMO 2026 Highlights – Part 1

87 min

Listen through the publisher, then discuss the episode here or arrange an in-person Roundtable. Your city determines where to meet.

Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.

In this episode of Lung Cancer Considered, Drs. Jacob Sands, Ferdinandos Skoulidis, and Jarushka Naidoo discuss key research highlights from ESMO 2026, including results from the DeLLphi-305 trial evaluating tarlatamab in extensive-stage small cell lung cancer and the KRAScendo-1 trial investigating divarasib in KRAS G12C-mutated NSCLC. The discussion also explores emerging immunotherapy strategies, including findings from the MOIO and OptiTROP-Lung06 studies, advances in predicting immune-related toxicities, and the potential implications of these developments for clinical practice. Jaruska Naidoo, MD Professor of Medical Oncology Royal College of Surgeons Consultant, Medical Oncologist at Beaumont Hospital X: @DrJNaidoo Instagram: jarushkanaidoo LinkedIn: https://www.linkedin.com/in/jarushka-naidoo-127a3b97/ Jacob Sands, MD Assistant Professor of Medicine, Harvard Medical School Associate Chief, Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute X: @sands_jacob Instagram: jacobsands LinkedIn: https://www.linkedin.com/in/jacobsands/ Ferdinandos Skoulidis, MD, PhD Professor, Department of Thoracic and Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center

Episode information is provided by the publisher. Listening takes place on the publisher’s service.

Listen at the source ↗

Featured places to meet in Palo Alto, CA

Explore these places and arrange a conversation through ThinkMatch.

City guide for Palo Alto, CA

More from Lung Cancer Considered

Lung Cancer Considered

ESMO 2026 Highlights – Part 2

60 min

In Part 2 of our ESMO 2026 Highlights series, Dr. Stephen Liu and Dr. Narjust Florez welcome Dr. Xiao-Rong Dong, Dr. Yi-Long Wu, and Dr. Chantal Decroisette to discuss three important clinical trials: SAFFRON, SANOVO, and PERSEE. The conversations explore emerging strategies for targeting MET in EGFR-mutated non-small cell lung cancer, advances in first-line immunotherapy, and the potential implications of these findings for clinical practice. Xiao-Rong Dong, MD, PhD ([email protected]) Professor, Chief Physician and Doctoral Supervisor Director, Department of Thoracic Oncology Cancer Center of Union Hospital, Huazhong University of Science and Technology No Social Chantal Decroisette, MD Thoracic Oncologist, Medical Oncology Department Centre Léon Bérard, Lyon No Social Yi-Long Wu, MD Professor, Guangdong Lung Cancer Institute Guangdong Provincial People’s Hospital Social: @ThomasW35874311

Discuss this episode

Lung Cancer Considered

LCC in Japanese: Respiratory Comorbidities in Lung Cancer

29 min

In this Japanese-language episode of Lung Cancer Considered, Dr. Misako Nagasaka speaks with Dr. Motoko Tachihara about managing lung cancer in patients with respiratory comorbidities, including interstitial lung disease (ILD), COPD, and pulmonary infections. They discuss key considerations for treatment selection, the use of emerging therapies in patients with pre-existing lung disease, and the importance of multidisciplinary care for these complex patients. Guest Host: Misako Nagasaka, MD, PhD Associate Clinical Professor University of California, Irvine X: @MNagasaka Guest Name & Title: Motoko Tachihara, MD, PhD Associate Professor Division of Respiratory Medicine, Department of Internal Medicine Kobe University Grade School of Medicine

Discuss this episode

Lung Cancer Considered

What’s on Your Plate Matters: Nutrition & Lung Cancer

51 min

In this episode of Lung Cancer Considered, host Dr. Narjust Florez is joined by Dr. Urvi Shah and Dr. Krystle Zuniga to explore the critical role of nutrition in lung cancer care. The discussion highlights current evidence on nutrition and cancer outcomes, practical strategies to support patients during treatment and survivorship, and common misconceptions fueled by misinformation. Together, they emphasize the importance of integrating evidence-based nutrition guidance into oncology practice to improve patient well-being and quality of life. Guests: Urvi Shah, MD, MS, DipABLM Hematologist, Oncologist, and Physician Scientist Memorial Sloan Kettering Cancer Center All Social: @UrviShahMD Krystle Zuniga, PhD, RD, CSO Owner, Cancer Nutrition HQ Assistant Professor of Instruction, Department of Nutritional Sciences University of Texas Austin Social: @cancernutritionhq

Discuss this episode

Community Poll

Essential public services should be protected even when they operate at a financial loss.

Share your view, then see how readers voted. No sign-in required. This poll is shared across stories.

Do you agree or disagree?

Choose one answer

Common Quandary

A Common Quandary to discuss

Another conversation to explore, separate from this news story.

Your coworker bends a dumb rule to help people. Do you report it?

An underpaid coworker quietly bends a company rule to help colleagues receive benefits they were technically denied. No customer is harmed, but the records are inaccurate and you are asked to certify them.

Where should loyalty end when a rule seems unjust?

Explore this quandary